Get Praxis Precision Medicines alerts:View Our Latest Analysis on Praxis Precision MedicinesInsiders Place Their BetsInstitutional Inflows and OutflowsIn other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of Praxis Precision Medicines stock in a transaction on Wednesday, June 24th. Praxis Precision Medicines News SummaryHere are the key news stories impacting Praxis Precision Medicines this week:Positive Sentiment: Praxis said it expects two FDA decisions within roughly six months and is targeting approximately $10 billion in peak sales for ulixacaltamide. Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last issued its earnings results on Thursday, August 6th. Praxis Precision Medicines Company Profile(Get Free Report)Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. Further ReadingReceive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.